Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology
News Release
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
What Happened To Puma Biotechnology?
Articles with Puma Biotechnology
Aung Myat - Assistant - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
Puma - Q2 earnings release
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
